Postoperative Crohn’s Disease
This chapter will cover prognostic and predictive biomarkers that have been identified in association with postoperative recurrence of Crohn’s disease. It will discuss the optimal management of Crohn’s disease following resectional surgery with reference to the natural history of Crohn’s disease after surgery, risk factors for earlier postoperative recurrence, diagnosis and monitoring of recurrence and therapeutic strategies to address prevention of recurrence. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.
- 2.Farmer RG, Hawk WA, Turnbull RB. Efficacy and complications of surgery for Crohn’s disease. Gastroenterol Hepatol. 2010;6(9):587–96.Google Scholar
- 27.Neurath M. Thiopurines in IBD. Gastroenterol Heaptol. 2010;6(7):435–6.Google Scholar
- 30.De Cruz P, Kamm MA, Hamilton AL, et al. Adalimumab prevents post-operative Crohn’s disease recurrence, and is superior to thiopurines: early results from the POCER study. Gastroenterology. 2012;142:S–212.Google Scholar
- 34.ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02834754, A randomised, double-blind, placebo controlled study of vedolizumab for the prevention of post-operative Crohn’s disease recurrence (Vedo Post-op); 2016 [cited 2017 Oct 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02834754.
- 35.Saffouri E, Kemp L, Muir A, et al. PTU-140 Vedolizumab is an effective therapy in postoperative ileal crohns following loss of response to anti-tnf. Gut. 2017;66:A119–20.Google Scholar